We describe here a clonal approach for efficient and robust construction of recombinant adenoviral genomes that holds certain advantages over existing approaches. Transgenes of interest are cloned into a small, conditionally replicating plasmid containing the left end of a recombinant adenoviral genome, encompassing pIX coding regions. Transformation of this plasmid into recombination-competent Escherichia coli bearing a plasmid containing the right end of a recombinant adenoviral genome, commencing from pIX coding regions, yields a stable co-integrated plasmid encoding a full adenoviral genome, by virtue of shared homology in pIX coding regions contained in both plasmids. The recombination process yielding the full adenoviral plasmid requires only one step, and always results in the formation of only the desired recombinant adenoviral genome. Thus, no screening is required to identify the correct plasmid encoding the desired recombinant adenoviral genome. In addition, the plasmid encoding the right-hand side of the adenoviral genome is itself incapable of producing contaminating adenovirus. We have successfully employed this approach to generate over 200 recombinant adenoviruses, obtaining only the desired recombinant adenoviral species each time. The process is amenable to medium-to-high-throughput parallel construction of adenoviral genomes, and as such should aid efforts aimed towards high-throughput functional annotation of therapeutic gene targets, which aim to leverage the benefits of adenoviruses as gene delivery and expression vectors.
We describe here a clonal approach for efficient and robust construction of recombinant adenoviral genomes that holds certain advantages over existing approaches. Transgenes of interest are cloned into a small, conditionally replicating plasmid containing the left end of a recombinant adenoviral genome, encompassing pIX coding regions. Transformation of this plasmid into recombination-competent Escherichia coli bearing a plasmid containing the right end of a recombinant adenoviral genome, commencing from pIX coding regions, yields a stable co-integrated plasmid encoding a full adenoviral genome, by virtue of shared homology in pIX coding regions contained in both plasmids. The recombination process yielding the full adenoviral plasmid requires only one step, and always results in the formation of only the desired recombinant adenoviral genome. Thus, no screening is required to identify the correct plasmid encoding the desired recombinant adenoviral genome. In addition, the plasmid encoding the right-hand side of the adenoviral genome is itself incapable of producing contaminating adenovirus. We have successfully employed this approach to generate over 200 recombinant adenoviruses, obtaining only the desired recombinant adenoviral species each time. The process is amenable to medium-to-high-throughput parallel construction of adenoviral genomes, and as such should aid efforts aimed towards high-throughput functional annotation of therapeutic gene targets, which aim to leverage the benefits of adenoviruses as gene delivery and expression vectors. Adenoviruses are well established as a means of gene expression in biological systems of interest and represent an alternative means of gene delivery with greater ease of use than lipid or salt delivery technologies. The inability of adenoviruses to integrate into (and thus not disrupt) the genomes of target cells, their wide range of potential target cells, and the ability to produce high titres of recombinant viruses (up to 10 11 particles/ml of culture medium) make them very attractive tools for gene expression studies. 1 Recombinant adenoviruses expressing a gene of interest can yield a homogeneous population (ie, B100%) of the target cell population expressing the transgene of interest. Additionally, the recent description of adenoviruses as tools for shortinterfering RNA (siRNA) expression 2,3 makes them powerful tools for analysis of gene function, considering that they can be applied as a 'one-stop' tool for both therapeutic gene overexpression and transcript suppression. For both preliminary in vitro validation followed by further in vivo validation, such viral vectors have few equals. Many approaches have been described for generating recombinant adenoviruses (rAV), principally involving direct plasmid construction of recombinant adenoviral genomes, [4] [5] [6] [7] [8] or indirect construction (two-plasmid systems). 3, [9] [10] [11] [12] [13] [14] [15] [16] In general, one-plasmid systems are limited by choice of suitable restriction sites and the difficulties encountered in manipulating such large plasmids (B50 kbp). Two-plasmid systems include approaches whereby a shuttle plasmid (or DNA fragment), containing an expression cassette, is combined with a second (larger) plasmid (or viral DNA fragment) containing the majority of the adenoviral coding regions by homologous recombination in Escherichia coli, [9] [10] [11] or in mammalian packaging cell lines. 3, [12] [13] [14] [15] Cre-lox-mediated rAV plasmid assembly has also been described, in both mammalian cell lines 13 and E. coli. 16 Additionally, methods for construction of adenoviral genomes by homologous recombination in yeast and their subsequent modification by two-step gene replacement have been described. 17, 18 Existing methods involving rAV plasmid construction in E. coli generally entail some form of screening to identify the correct rAV-containing plasmid. [5] [6] [7] 10, 11 Homologous recombination in packaging cell lines may require that the resulting rAV are isolated and identified by plaque purification, 6, 15 unless cell lines such as PER.C6 are employed. 3, 14, 19 Many of these approaches have been applied to the construction of adenoviral libraries containing populations of transgenes of interest. 3, 7, 8, [14] [15] [16] However, such approaches may require specific cell lines, 3, 7, 14 screening to identify the correct rAV, 7, 15, 16 or plasmid DNA modification by techniques not amenable to high-throughput formatting. 16 Additionally, such approaches may entail pooling rAV plasmids, and as such are not clonal, 8, 16 and give rise to the possibility of undesirable rAV species arising from inter-rAV recombination. The approach we describe here is 100% efficient and clonal, thus obviating the need for screening, and enables rAV plasmid construction with generic materials.
By this approach, transgenes of interest are cloned into the multiple cloning site of a shuttle plasmid, pCA350 (Figure 1a ). pCA350 contains nucleotides 1-382 of the adenoviral serotype 5 genome, 20 encoding the left ITR and the packaging sequence (C), followed by a human CMV immediate early promoter, multiple cloning site, SV40 polyA signal, modified Ad pIX coding regions, an R6Kg conditional bacterial origin of replication, and a kanamycin resistance cassette. The R6K conditionally replicating plasmid system 20, 22 is composed of two principal components: a conditional origin of replication (R6Kg) and a specific replication initiator (rep) protein complex, comprising two p proteins, 35 and 30.5 kDa, both encoded by the pir gene. 22 R6Kg plasmid replication does not occur in the absence of p proteins, whereas low intracellular levels of p activate replication, and high levels inhibit replication. Thus, plasmids bearing an R6Kg ori cannot replicate in E. coli strains not expressing pir gene products, and thus cannot subsequently confer antibiotic resistance markers unto the bacterial culture. This provides a ready means of selection, either for or against, E. coli bearing such R6Kg plasmids, based on the presence or absence of the pir gene products. 23 Any desired recombinant pCA350/GeneX plasmid can be selected after propagation in E. coli strains expressing the p proteins, such as RapidTrans E. coli l Pir+ TAM1 (Active Motif, Carlsbad, CA, USA), which allow replication of plasmids with an R6Kg origin of replication. . pOSE3700 (not shown) contains an identical adenoviral 5 genome carrying the same E3 region deletions 10 in addition to a deletion in the E4 region 24, 25 (corresponding to nts 33 423-35 356 20 ). Recombinant adenoviruses derived from pOSE3700 require growth on E4-complementing cell lines, such as IGRP2. 24, 25 The pIX and IVa2 coding regions have been modified to reduce RCA emergence when HEK293 is used as the packaging cell line, as described previously. 23 Specifically, both pOSE1700 and -3700 are degenerated in regions of homology with the adenoviral fragment stably integrated in HEK 293 cells 26 (specifically at pIX and part of IVa2 coding regions), allowing codon-optimised expression of the required adenoviral proteins, but with a substantially reduced risk of emergence of replicative competent adenovirus (RCA). 23 Thus, the safety profile of viruses generated by this approach is better than viruses generated by more classic methodologies. Earlier versions of these pOSE plasmids also exist, called pOSE1000 and pOSE3000, which are identical to pOSE1700 and pOSE3700, respectively, but lack modified Ad5 pIX and IVa2 regions, 23 and thus represent a more generic version of E1E3-deleted rAV genomes. pOSE1700 was generated by EDRAG from an incP-derived replicon containing an E1E3-deleted Ad5 genome expressing LacZ, as previously described, 10 and as outlined in Figure 2 . EDRAG or E. coli-Derived Recombinant Adenoviral Genome technology is a plasmid-based, multi-step approach to generate and introduce changes into recombinant adenoviral genomes. 10 Desired recombinant pCA350/GeneX plasmids are transformed into competent Tet R E. coli JM83 (ATCC cat. no. 35607) already carrying plasmid pOSE1700 or pOSE3700. JM83 are a recombinant-competent E. coli strain of genotype F-ara D(lac-proAB) rpsl (Str r ) (F80dlac D (lacZ) M15). pCA350 and pOSE each contain 766 bp of identical sequence homology, encompassing pIX coding regions, which enables homologous recombination between these two plasmids in suitable bacterial strains (Figure 1c) . Propagation of the subsequent co-integrated plasmid is maintained both by antibiotic selection and by use of specific bacterial replication origins. The cointegrated pAD plasmid expresses both Tet and Kan resistance markers. Given that the Kan R -expressing pCA350 plasmid is incapable of independent replication in non-p protein-expressing bacterial strains 21, 22 (such as JM83), pCA350 and pOSE cannot be maintained as independent plasmids in the same bacterium. Any resulting Tet R /Kan R E. coli JM83 colonies can only contain pAd.
As an example (the process is identical for any transgene employed), a pCA350 plasmid containing a firefly luciferase expression cassette, pCA350/Luc, was constructed. This plasmid was transformed into competent Tet R E. coli JM83/pOSE1700 and plasmid DNA isolated from 15 individual colonies arising from the transformation. EcoRI restriction digestion patterns show that the only plasmid species obtained after OSEDRAG between pCA350/Luc and pOSE1700 was the desired pAdDE1-CMV-Luc (Figure 3) . No plasmid matching the expected pattern of pOSE1700, or any other aberrant plasmid species, was found. As such, OSEDRAG, or Figure 1 One-step E. coli-Derived Recombinant Adenoviral Genome construction. (a) Plasmid pCA350 was derived from plasmid pIG5 23 by removal of sacB-and nls-LacZ coding regions, employing standard molecular biology techniques. 29 The ITR and C span from nts 1-380 of the adenoviral 5 genome. 20 Transgenes of interest can be cloned by standard approaches into the MCS, which is flanked by a full human CMV immediate early promoter and an SV40 polyA signal. The R6Kg origin of replication only allows plasmid replication in the presence of the p protein (see the main body of text for a fuller explanation). 21, 22 (b) Plasmid pOSE1700 was generated as described in Figure 2 . (c) Homologous recombination between pCA350 (black boxes, white lettering) and pOSE1700 (white boxes, black lettering) is facilitated by a shared region of 766 bp of homology in pIX coding regions. Recombination results in the formation of a co-integrated plasmid which reconstitutes the left ITR and C in relation to the downstream sequences already contained in pOSE1700, yielding an adenoviral genome capable of replication in packaging cell lines. (d) Restriction digestion by PacI to free the adenoviral coding regions from the pAd background and subsequent transfection into HEK 293 cell lines yields a homogeneous population of recombinant adenoviral particles after a 10-21-day growth period.
One-step adenoviral vector construction
B Mullan et al one-step E. coli-Derived Recombinant Adenoviral Genome technology (Figure 1 ) is similar to EDRAG described earlier (Figure 3 ), but only requires one step to generate the desired recombinant adenoviral genome. One E. coli/JM83 . pAdDE1-CMV-Luc bacterial clone was selected to inoculate a large liquid culture, and plasmid DNA was prepared using the Large Construct Kit (Qiagen, Valencia, CA, USA). pAD1.7ExpLuc DNA was digested with PacI to liberate the adenoviral ITRs and then transfected into HEK 293 cells using Effectene (Qiagen). DNA (1 mg) was mixed with 50 ml Buffer EC, then sequentially with 8 ml enhancer and 15 ml Effectene.
One-step adenoviral vector construction B Mullan et al
The transfection complexes were brought to a final volume of 600 ml in serum-free DMEM (Gibco, Carlsbad, CA, USA; Cat. no. 41965-039), and incubated on HEK 293 monolayers in six-well plates for 3-6 h, before adding 2.5 ml DMEM/10% FBS. After 2 days, cells and media were transferred to a 75 cm 2 flask and allowed to propagate until the entire culture displayed adenoviralinduced cytopathogenicity. Freeze-thawed lysates were used to infect 1500 cm 2 of HEK 293 cells, from which the viral particles in the freeze-thawed cell pellet 3 days One-step adenoviral vector construction B Mullan et al post-infection was isolated by separation on two successive cesium chloride gradients. Typically obtained yields were 10 12 viral particles per batch, as assessed by standard HPLC analysis. 27 We have employed this approach to generate over 200 recombinant adenoviral genomes. The only plasmid species ever obtained after OSEDRAG was one containing the reconstituted E1E3-deleted recombinant adenoviral genome, pAd. As such, this approach to recombinant adenoviral (rAd) plasmid construction is truly clonal as it obviates the need for screening of resultant recombined pAD plasmids, which is a caveat of other approaches. This approach is readily applicable with commonly sourced materials, requiring neither specific packaging cell line clones, nor the expression of recombinases, etc. In addition, the tendency of pAd generated by OSEDRAG to recombine with the Ad5 fragment contained in 293 cells has been crippled, 23 increasing the safety profile of the resultant rAd without recourse to specific cell lines such as PER.C6. 19 The pAds obtained by this method are stable, and their DNA yields clean, interpretable restriction patterns, without the requirement of subtransforming into other E. coli strains.
Additionally, the shuttle plasmid carrying the left end of the adenoviral genome (pCA350) is of a sufficiently small size (4575 bp) to allow easy subcloning of the desired transgenes into its cloning site. In fact, most recently, we have constructed a newer version of pCA350, pSHDest01, which is identical to pCA350, except that it enables ligase-free subcloning of transgenes using Gateway technology (Invitrogen, Carlsbad, CA, USA). Using an approach employing pSHDest01 in place of pCA350, we have established conditions for mediumto high-throughput parallel construction of recombinant Figure 2 Construction of a plasmid encoding the right-hand side of the Ad5 genome (pOSE1700) by EDRAG. (a) Plasmid pJJ301 was constructed in a pIG5 23 plasmid background by removal of all adenoviral-(5 0 ITR, C, pIX and IVa2 coding regions), and nls-LacZ coding sequences, followed by insertion of desired elements, by standard molecular biology techniques. 29 This plasmid contains an 'upstream region' (UR) (a PCR fragment amplified from nt 57 627 to 57 951 of pAdDE1-CMV-nlsLacZ (pXL2822 10 ), which confers 325 bp of sequence homology with pAdDE1-CMV-nlsLacZ), modified pIX and IVa2 coding regions (a complete Syngen #2 fragment 23 ), nts 4355-5191 of Ad5 IVa2, 20 which confer 848 bp of sequence homology with pAdDE1-CMV-nlsLacZ, the sacB gene of Bacillus subtilus, which is lethal to E. coli in the presence of sucrose 30, 31 (and was taken from pXL2756 10 ), an R6Kg conditional bacterial origin of replication, 21, 22 and a transposon incorporating a Kanamycin resistance cassette. 32, 33 (b) pAdDE1-CMV-nlsLacZ, which has been described (as pXL2822) previously, 10 consists of an E1E3-deleted recombinant Ad5 genome expressing LacZ with an N-terminally fused nuclear localisation signal (under control of a CMVie promoter) inserted into an E. coli incompatibility group P (incP)-derived replicon containing a vegetative origin of replication (oriV). (c) Transformation of Tet R E. coli JM83 already carrying pAdDE1-CMV-nlsLacZ (white boxes, black lettering) by pJJ301 (black boxes, white lettering) results in homologous recombination between the two plasmid species via the UR or IVa2 regions of shared homology under Tet+Kan selection pressure, yielding two possible co-integrated plasmid species. pAdDE1-CMV-nlsLacZ and pJJ301 cannot grow independently in a given E. coli JM83 Tet R / Kan R clone as pJJ301 cannot replicate in the absence of p protein. 22 Removal of Kanamycin selection pressure from Tet R /Kan R E. coli JM83/pAdDE1-CMVnlsLacZ . pJJ301 leads to a second resolving recombination event (grey arrows), yielding two possible resolved plasmid species. Growth in the presence of 5% sucrose negatively selects for any E. coli expressing the sacB gene product. The two final plasmid species obtained are the starting pAdDE1-CMV-nlsLacZ plasmid, which yields blue colonies on LB/Tet/Sucrose/X-Gal selection media, and pOSE1700 (boxed), which yields white colonies on the same media. The CMV-driven LacZ expression cassette is sufficiently functional in E. coli to generate a LacZ + phenotype (blue) in these bacteria. In all, 12.5 mg/ml Tet, 50 mg/ml Kan, and 5% sucrose were the employed concentrations of these agents. Figure 3 Construction of a plasmid encoding a recombinant Ad5 genome expressing firefly luciferase (pAdDE1-CMV-Luc) by OSEDRAG. A PCR fragment bearing the coding regions for firefly luciferase (Luc) was generated from pIG18, 23 which expresses firefly luciferase, using a suitable primer set. The amplified product was subcloned into pCA350 by standard procedures. 29 In all, 20 ng of the ligation reaction between Luc-PCR fragment and pCA350 was transformed into transformation-competent RapidTrans E. coli Pir+TAM1 (Active Motif), and selected on Kan-containing growth media. A resultant pCA350/Luc plasmid was obtained after restriction digest confirmation of mini-prep DNA. Plasmid pOSE1700 (400 ng) was transformed into calcium chloride-competent E. coli JM83, to obtain Tet R E. coli JM83/pOSE1700, which was subsequently transformed with 400 ng of pCA350/Luc. Transformants were selected on Kan-and Tet-containing growth media for 24 h. Plasmid DNA was isolated from 15 individual colonies arising from the transformation by a modified SDS lysis procedure. 29 All plasmid DNAs were digested with EcoRI and the digested products electrophoresed on 1% agarose gels and stained with ethidium bromide. Expected restriction patterns for both pAdDE1-CMV-Luc (1-15, for each independently obtained plasmid) and pOSE1700 are shown apposed (in boxes) to the gel. An EcoRI digestion of pOSE1700 (far left) was co-electrophoresed for reference.
One-step adenoviral vector construction B Mullan et al adenoviral genomes up to 96-well format. The ease of generation of shuttle plasmids coupled with guaranteed one-step production of pAd combines to make this platform very amenable to medium-to high-throughput production of rAV for functional gene annotation.
Finally, the plasmid pJJ301 enables efficient conversion, by EDRAG, 10 of any plasmid containing a recombinant adenoviral genome (bearing suitable regions of homology to pJJ301) into a corresponding pOSE, following a schema essentially identical to that outlined in Figure 3 . These new pOSE plasmids allow subsequent generation of multiple rAVs by OSEDRAG. In this manner, we have generated pOSE plasmids bearing modified capsid regions for rAV re-targeting strategies (from parental plasmids containing full rAV genomes bearing this capsid modification), 28 and applied them to parallel generation (by OSEDRAG) of multiple retargeted rAd expressing genes of interest.
The sole caveat of this technology is that shuttle plasmids bearing homology with E. coli chromosomal regions may give rise to integrative events in E. coli after transformation. Specifically, in the case of transformation of pCA350/LacZ into E. coli JM83, it was observed that Tet R /Kan R /LacZ + colonies were obtained, which did not contain episomally replicating plasmid. This appeared to be due to homologous recombination between the LacZ regions of the shuttle plasmid and those in the E. coli JM83 chromosome. However, inoculation of liquid cultures with E. coli JM83/pOSE1700+pCA350/LacZ transformants shortly after transformation (1 h), incubation overnight in the presence of antibiotics, and retransformation of extracted pAD1.7ExpLacZ plasmid DNA into E. coli JM83 gave rise to episomally replicating pAd.
In conclusion, we have described a robust approach for the construction of recombinant adenoviral genomes that yields the desired transgene-carrying recombinant adenoviral genome 100% of the time. The resulting plasmid containing the recombinant adenoviral genome is truly clonal, obviating the need for screening, and the individual component parts of the construction process are themselves incapable of generating contaminating adenoviral species. The steps involved in construction of the component parts are transferable to enable creation of similarly formatted systems representing modified adenoviral genomes, and the technology has proven amenable to medium-to high-throughput formatting.
